; Whereas studies suggest that the overall risk of developing Tardive Dyskinesia after taking DRBAs is between 10 and 30 percent; Whereas it is estimated that over 600,000 people in the United States suffer from Tardive Dyskinesia; Whereas, according to the National Alliance for Mental Illness, 1 in every 4 patients receiving long-term treatment with an antipsychotic medication will experience Tardive Dyskinesia; Whereas years of difficult and challenging research have resulted in recent scientific breakthroughs, with 2 new treatments for Tardive Dyskinesia approved by the Food and Drug Administration of the Department of Health and Human Services; Whereas Tardive Dyskinesia is often unrecognized, and patients suffering from the illness are commonly misdiagnosed; Whereas regular screening for Tardive Dyskinesia in patients taking DRBA medications is recommended by the American Psychiatric Association; Whereas patients suffering from Tardive Dyskinesia often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; Whereas caregivers of patients with Tardive Dyskinesia face many challenges and are often responsible for the overall care of the Tardive Dyskinesia patient; Whereas the Senate can raise awareness of Tardive Dyskinesia in the public and medical community: Now, therefore, be it